Healthcare & Insurance
Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, presented preclinical results of TNX-801 (live virus vaccine for percutaneous administration) to potentially prevent smallpox and
Wednesday, January 29, 2020
CymaBay Publishes Shareholder Letter
NEWARK, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the publication of a Letter to Shareholders. In this
Wednesday, January 29, 2020
Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that translational data supporting the
Wednesday, January 29, 2020
Albireo Announces Proposed Public Offering of Common Stock
BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of its common stock. In connection with the
Wednesday, January 29, 2020
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and
Montrouge, France, January 29, 2020 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position DBV Technologies (the “Company”) (Euronext: DBV – ISIN:
Wednesday, January 29, 2020
Trupanion, Inc. Announces Fourth Quarter and Full Year 2019 Earnings Release and Conference Call
SEATTLE, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, announced today it will report financial results for its 2019 fourth quarter and full year after the market closes on Thursday, February 13, 2020. The company will
Wednesday, January 29, 2020
Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases
— Reiterates Top Line Data on Phase 3 in PFIC Expected Mid-2020 —— To Initiate Pivotal Trials in Biliary Atresia and Alagille Syndrome in 2020 — BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company
Wednesday, January 29, 2020
Medigene, IRICoR and Université de Montréal Sign Collaboration and Exclusive Licensing Option on Novel Cancer Antigens
MARTINSRIED, Germany and MUNICH, Germany and MONTRÉAL, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, announces today that it has entered into a research
Wednesday, January 29, 2020
Align Technology Announces Fourth Quarter and Fiscal 2019 Financial Results
Achieves 8 Millionth Invisalign Patient Milestone2019 revenues up 22.4% to a record $2.4 billion, clear aligner revenues a record $2 billion2019 diluted EPS of $5.532019 Invisalign volume up 24.2% to a record of 1.5 million cases2019 iTero scanner and services revenues up 38.5% to a record $381.0
Wednesday, January 29, 2020
LeMaitre Vascular Will Announce Fourth Quarter 2019 Earnings Results on February 6, 2020
BURLINGTON, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2019 financial results on Thursday, February 6, 2020, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day
Wednesday, January 29, 2020
Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer
The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in 2nd line maintenance treatment of relapsed ovarian cancerPARIS, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ
Wednesday, January 29, 2020
Crossject : Information relative au nombre de droits de vote et d'actions composant le capital social
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 29 janvier 2020 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de
Wednesday, January 29, 2020
Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate
WAKEFIELD, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, has further engaged Locust Walk, a leading global life sciences transaction firm serving as its strategic advisor, to lead the
Wednesday, January 29, 2020
COCRYSTAL PHARMA, INC. PRICES $2.2 MILLION REGISTERED DIRECT OFFERING
BOTHELL, WA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the pricing of a registered direct offering with gross
Wednesday, January 29, 2020
Chr. Hansen Holding A/S - Major shareholder announcement from BlackRock, Inc.
Company announcement No. 6/2020 For further information please contact:Martin Riise, Senior Director, Investor Relations, Tel: +45 5339 2250Annika Stern, Investor Relations Officer, Tel: +45 2399 2382Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384 Attachment
Wednesday, January 29, 2020
Reliance Global Group, Inc. Announces Appointment of Ben Fruchtzweig and John Lowy to the Board of Directors; Ben Fruchtzweig and Scott Korman
Appointments Fulfill Key Steps Towards Meeting the Requirements of OTCQB Venture Market and Listing on a National Stock Exchange LAKEWOOD, NJ, Jan. 29, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Reliance Global Group, Inc. (OTC: RELI) ("RELI" or the "Company"), today announced that Ben
Wednesday, January 29, 2020
TOMI’s SteraMist Preparedness for Aiding in the new Coronavirus-Wuhan or 2019-nCoV Outbreak
BEVERLY HILLS, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (OTCQB:TOMZ), is a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a
Wednesday, January 29, 2020
Assure Holdings Performs First Neuromonitoring Case in South Carolina
Geographic Expansion Continues as the Company Begins Providing Services in Seventh StateDENVER, Colo., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to
Wednesday, January 29, 2020
Livongo to Release Results for the Fourth Quarter of Fiscal Year 2019
MOUNTAIN VIEW, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc., (Nasdaq: LVGO) today announced it will hold a conference call on Monday, March 2, 2020, after close of the U.S. stock market at 4:30 p.m. Eastern Time to discuss results for the fourth quarter and full year 2019.
Wednesday, January 29, 2020
Artelo Biosciences to Present at the LSX World Congress in London
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the LSX World Congress to be held on February
Wednesday, January 29, 2020
